MB49 Orthotopic Mouse Model Service for Bladder Cancer

The MB49 orthotopic mouse model remains one of the most physiologically relevant preclinical platforms for studying bladder cancer progression, intravesical therapy response, and tumor-immune crosstalk within the native urothelial microenvironment. At Alfa Cytology, we engineer this syngeneic orthotopic system with surgical precision and rigorous quality controls, delivering reproducible tumor take rates and comprehensive pharmacodynamic readouts tailored to your discovery pipeline.

Overview of MB49 Orthotopic Mouse Model for Bladder Cancer

The MB49 cell line was originally established from primary bladder epithelial explants of a C57BL/6 mouse following in vitro exposure to 7,12-dimethylbenz[α]anthracene (DMBA) for 24 hours, yielding a chemically induced urothelial carcinoma that closely mirrors the epithelial nature and molecular landscape of human muscle-invasive bladder cancer. When implanted orthotopically into the bladder lumen of syngeneic C57BL/6 hosts, MB49 cells recapitulate critical features of the disease, including luminal tumor growth, stromal invasion, and a myeloid-dominated "cold" tumor microenvironment characterized by abundant polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) and comparatively sparse CD8⁺ T-cell infiltration. This immunosuppressive milieu closely resembles a substantial fraction of human bladder tumors, making the model exceptionally valuable for dissecting mechanisms of immune evasion and evaluating immunomodulatory strategies.

Fig 1. Representative near-infrared fluorescence (NIRF) imaging of MB49 bladder cancer with ASP5354. (Teranishi, Katsunori, 2023)

Orthotopic instillation of MB49 cells—typically performed via transurethral catheterization following chemical preconditioning of the urothelium—preserves the anatomical integrity of the bladder wall, maintains exposure to urine-specific factors, and permits organ-specific immune recruitment patterns that are absent in subcutaneous counterparts. The model supports a broad spectrum of research applications, from intravesical Bacillus Calmette-Guérin (BCG) immunotherapy and gene-therapy vector testing to checkpoint inhibitor timing studies and chemokine-targeting investigations. Tumor burden can be tracked longitudinally through bioluminescence imaging of luciferase-tagged derivatives (MB49-luc), urinary biomarker analysis, or terminal histopathological examination, providing flexible and robust endpoints for preclinical drug development.

Cell Line Information: MB49

MB49 is a murine transitional cell bladder carcinoma line with well-documented origins, growth characteristics, and immunological profile. The table below summarizes essential parameters for researchers considering this model in preclinical bladder cancer studies.

Our Services

Alfa Cytology specializes in the design, execution, and analytical support of orthotopic bladder cancer models, leveraging stringent surgical protocols, pathogen-free animal husbandry, and multimodal tumor monitoring to generate high-fidelity preclinical datasets. Whether your program requires standard MB49-luc bioluminescence tracking, custom chemokine-profiling panels, or combination-therapy arm designs, our team provides end-to-end project management—from pilot feasibility through terminal necropsy and tissue archiving—ensuring data integrity and regulatory compliance at every stage.

Workflow of MB49 Orthotopic Mouse Model Construction

Construction of the MB49 orthotopic bladder tumor model demands meticulous attention to urothelial preconditioning, aseptic surgical technique, and precise cell delivery to achieve consistent tumor engraftment while minimizing perioperative morbidity. The workflow outlined below reflects best-practice methodologies validated in peer-reviewed preclinical studies.

1. Cell Preparation and Quality Control: MB49 cells are expanded under standard culture conditions and harvested during exponential growth phase. Viability is assessed by trypan blue exclusion; only suspensions with >80% viability are qualified for implantation. Cells are washed three times in serum-free DMEM to eliminate residual FBS, then resuspended at a concentration of 2×10⁶ cells/mL (or as specified by the study design) and maintained on ice until instillation.
2. Animal Preparation and Anesthesia: Female C57BL/6 mice, aged 6–10 weeks, are acclimatized for a minimum of one week prior to surgery. On the procedure day, mice receive intraperitoneal anesthesia (e.g., ketamine/medetomidine cocktail at 75 mg/kg and 1 mg/kg, respectively), with depth of anesthesia confirmed by absence of toe-pinch reflex. Ophthalmic ointment is applied to prevent corneal desiccation, and animals are positioned supine on a heated surface with hind limbs gently secured.
3. Urothelial Preconditioning: A 24-gauge intravenous catheter is inserted transurethrally into the bladder under sterile conditions. Residual urine is evacuated by gentle abdominal pressure. The bladder mucosa is preconditioned with either poly-L-lysine (PLL, 50 µL, instilled slowly at 10 µL per 20 seconds and retained for 20 minutes) or 22% ethanol (100 µL for 15 minutes) to disrupt the urothelial barrier and enhance tumor cell adhesion. The preconditioning agent is then aspirated.
4. Intravescial Cell Instillation: The prepared MB49 cell suspension (typically 5×10⁴ to 1×10⁵ cells in 50 µL serum-free medium) is instilled through the catheter at a controlled rate of 10 µL per 20 seconds. Slow delivery is critical to prevent vesicoureteral reflux and subsequent upper-tract tumor seeding. The catheter is clamped or sealed to retain the inoculum within the bladder lumen for 60 minutes.
5. Post-Instillation Recovery and Monitoring: Following the retention period, the catheter is removed and the bladder is emptied by gentle abdominal compression. Mice are revived with an appropriate reversal agent (e.g., atipamezole) and returned to warmed recovery cages. Body weight, hydration status, and general behavior are monitored daily for the first 72 hours, with analgesia provided according to institutional guidelines.
6. Longitudinal Tumor Monitoring: For MB49-luc studies, tumor establishment and growth are quantified via bioluminescence imaging following intraperitoneal D-luciferin injection (150 µg/g body weight) using an IVIS or equivalent imaging system, typically performed twice weekly during the first three weeks. Complementary assessments include periodic body-weight recording, hematuria observation, and—where applicable—urinary biomarker analysis or ultrasound imaging.
7. Endpoint Procedures and Tissue Collection: Mice are euthanized upon reaching predefined humane endpoints (e.g., significant weight loss, pronounced hematuria, or tumor burden exceeding protocol limits). The bladder is excised, weighed, and processed for downstream analyses including formalin-fixed paraffin-embedded (FFPE) histology, frozen-section immunofluorescence, flow-cytometric immune profiling, and molecular extraction (RNA/DNA/protein) as dictated by the study objectives.

Fig 2. MB49 Orthotopic Mouse Model construction workflow.

Case Study-MB49 Orthotopic Mouse Model Development

In a recent preclinical engagement, Alfa Cytology established an orthotopic MB49-luc bladder tumor cohort to support a client's intravesical immunotherapy program. Following standardized urothelial preconditioning and transurethral instillation, tumors were successfully engrafted across the entire study population, with bioluminescence signal detectable within one week and exponential growth kinetics observed through day 21. The study incorporated multiple treatment arms—including an intravesical BCG comparator, a novel adenoviral vector candidate, and an anti-PD-1 systemic combination—enabling parallel assessment of local immune activation, systemic pharmacodynamics, and bladder-specific toxicity profiles. Terminal analyses revealed treatment-dependent modulation of PMN-MDSC infiltration and PD-L1 expression dynamics, yielding actionable insights that directly informed the client's subsequent IND-enabling strategy.

Why Choose Alfa Cytology?

Partnering with Alfa Cytology for your MB49 orthotopic bladder cancer model delivers more than a standard tumor-bearing cohort; it provides a scientifically rigorous, customizable preclinical platform engineered to accelerate your therapeutic discovery timeline.

• Surgical expertise in transurethral orthotopic implantation ensures high tumor take rates and minimal procedural variability across replicate cohorts.
• Multimodal tumor monitoring—including bioluminescence imaging, ultrasound, and urinary biomarker analysis—offers flexible, non-invasive longitudinal readouts tailored to compound mechanism.
• Immunocompetent syngeneic modeling preserves native tumor-immune crosstalk, enabling robust evaluation of immunotherapies, checkpoint inhibitors, and myeloid-targeting agents.
• Customizable study designs accommodate combination-therapy arms, intravesical versus systemic dosing routes, and time-staggered treatment initiation to mirror clinical sequencing.
• Comprehensive endpoint analytics encompass flow-cytometric immune profiling, multiplex immunohistochemistry, RNA-seq, and pharmacokinetic tissue distribution studies.
• All studies are conducted under strict SPF husbandry and IACUC-approved protocols, with full chain-of-custody documentation and GLP-compatible data packages available.

Contact Us

If you are advancing a bladder cancer therapeutic candidate and require a validated, immunocompetent orthotopic model with robust translational relevance, reach out to Alfa Cytology today. Our scientific team is ready to discuss your specific program requirements, design a customized MB49 orthotopic study plan, and provide a detailed quotation aligned with your discovery milestones. Contact us now to accelerate your preclinical development with confidence.

For research use only. Not intended for any clinical use.